Page 6 - Lancet Report

Unlike Delta variant, Omicron less likely to cause long Covid: Lancet study

The Omicron variant of the SARS-CoV-2 virus is less likely to cause long COVID than the Delta strain, according to a study published in The Lancet journal. Long COVID is defined as having new or ongoing symptoms four weeks or more after the start of the disease, the researchers said. Symptoms include fatigue, shortness of breath, loss of concentration, and joint pain, which can adversely affect day-to-day activities, and in some cases can be severely limiting, they said. The researchers found that the odds of experiencing long COVID were between 20-50 per cent less during the Omicron period versus the Delta period, depending on age and time since vaccination. "The Omicron variant appears substantially less likely to cause Long-COVID than previous variants but still 1 in 23 people who catch COVID-19 go on to have symptoms for more than four weeks," said study lead author Claire Steves from King's College London, UK. The study identified 56,003 UK adult cases first testing positive

Bharat Biotech's Covaxin is safe for children between 2 and 18 yrs: Lancet

Data from over 50 million doses reveals minimal side effects

Some antivirals may be effective against Monkeypox virus: Lancet

A team of researchers have found that some antiviral medications might have the potential to shorten symptoms and reduce the amount of time a patient is contagious with Monkeypox virus.

Siga Tech's tecovirimat drug could help counter monkeypox, says study

The scientists said more work is needed to reach any conclusions but their study found little evidence that another drug, brincidofovir, was beneficial

Antiviral drugs could reduce monkeypox symptoms, says Lancet study

The research also reported the patient response to the first off-label use of two different antiviral medications -- brincidofovir and tecovirimat -- to treat the disease

Lancet publishes phase-3 trial data of Zydus' Covid vaccine ZyCoV-D

According to Zydus, the plug-and-play technology of the vaccine equips it to adapt to the rapidly mutating SARS COV-2 virus.

'Speculative, misinformed': Govt on Lancet's report on high Covid mortality

The Lancet reported on Thursday that the country accounted for around 22.3 per cent of global excess deaths as of December 31, 2021

Covid vax effectiveness declines after 6 months without boosters: Study

The study indicated that vaccines were 94 per cent effective at preventing hospitalisation 50-100 days after receiving the shot but fell to 80.4 per cent 200-250 days later

Booster gives antibody protection against Omicron variant: Lancet

Overall, antibody levels were nearly 2.5 times higher against Omicron after three doses compared to after two jabs

Booster dose provides good antibody protection against Omicron: Lancet

A third 'booster' dose of Covid-19 vaccine successfully raises antibody levels that neutralise the Omicron variant, according to laboratory findings.

Bharat Biotech updates Covaxin efficacy to 65.2% against Delta variant

Experts say more real-world studies are required now

Bharat Biotech's Covid-19 vaccine Covaxin gets mixed review from Lancet

Extrapolating from the report, Lancet said 'two doses offer 77.8 per cent protection against symptomatic Covid-19'.

Covid-19 can be transmitted by fully vaccinated people at home: Lancet

The study enrolled 621 participants, identified by the UK contact tracing system, between September 2020 and September 2021.

Antidepressant fluvoxamine may reduce risk of Covid-19 hospitalisation

Researchers treated 739 randomly selected Brazilian COVID-19 patients with fluvoxamine, with another 733 receiving a placebo, between January 15 to August 6 of this year.

Future health depends on radical change in digital technologies: Report

Digital technologies are transforming all areas of life and health, a trend that has been accelerated by the Covid-19 pandemic, but the benefits of these advances are not reaching everyone equally.

Data shows booster Covid shots 'not appropriate' for public: Lancet

Vaccine efficacy against severe Covid-19 is so high, even for the Delta variant, that booster doses for the general population are "not appropriate" at this stage in the pandemic, a Lancet report said

Covid vaccine boosters not 'appropriate' at this stage: Lancet study

Vaccine efficacy against severe Covid-19, even for delta variant, is so high that booster doses for the general population are not appropriate at this stage in pandemic, according to a Lancet review

India needs to do more on hypertension, says Lancet global survey

Marginal increase in the number of people living with the ailment but diagnosis, treatment and control still need to catch up with best practices

Covid vaccine benefits far outweigh rare risk of facial paralysis: Lancet

The beneficial effects of COVID vaccines far outweigh the risk of facial paralysis on one side of the face known as Bell's Palsy, confirms a study published in The Lancet Infectious Diseases journal

India Covid Dispatch: Experts say it's time to send kids back to schools

Flu shot may protect against severe Covid effects, long-lasting Covid symptoms rare in children and other stories from around the country on the fight against the pandemic